Vincerx Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022

Rhea-AI Summary

Vincerx Pharma, a clinical-stage biopharmaceutical company, announced a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022, scheduled for April 8-13, 2022, in New Orleans and virtually. The poster, titled "VIP152, a selective CDK9 inhibitor, demonstrates sensitivity in gynecologic cell lines that are cisplatin sensitive or resistant and delivers in vivo antitumor efficacy," will be presented by Melanie Frigault, PhD, on April 11 at 1:30 PM CT. Presentation materials will be available on Vincerx's website after the event.

Positive

• Scheduled presentation at a major cancer research event enhances visibility.
• Research on VIP152 may indicate promising therapeutic applications in oncology.

Negative

• Lack of specific financial metrics or data on VIP152's efficacy raises concerns over potential market impact.

PALO ALTO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced a poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, being held virtually and in New Orleans, Louisiana from April 8-13, 2022.

Poster presentation details:
Poster Title:	VIP152, a selective CDK9 inhibitor, demonstrates sensitivity in gynecologic cell lines that are cisplatin sensitive or resistant and delivers in vivo antitumor efficacy
Abstract Number:	4939
Presenter:	Melanie Frigault, PhD
Session Type:	In-Person and e-Poster Presentation
Session Title:	Mechanisms of Drug Action 2
Session Time:	April 11, 2022 at 1:30PM CT
Location:	Poster Section 25

A copy of the presentation materials can be accessed on the Investors section of the Company’s website at www.vincerx.com once the presentation has concluded.

About Vincerx Pharma, Inc.
Vincerx Pharma, Inc. (Vincerx) is a clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. Vincerx has assembled a management team of biopharmaceutical experts with extensive experience in building and operating organizations that develop and deliver innovative medicines to patients. Vincerx’s current pipeline is derived from an exclusive license agreement with Bayer and includes a clinical-stage and follow-on small molecule drug program and a preclinical stage modular bioconjugation platform, which includes next-generation antibody-drug conjugates and innovative small molecule drug conjugates. For more information, please visit www.vincerx.com.

Contacts
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
bmackle@lifesciadvisors.com

FAQ

What is the significance of Vincerx's poster presentation at AACR 2022?

The presentation highlights Vincerx's research on VIP152, potentially positioning the company as a key player in cancer therapeutics.

When is Vincerx's poster presentation scheduled?

It is scheduled for April 11, 2022, at 1:30 PM CT.

What does VIP152 target?

VIP152 is a selective CDK9 inhibitor that shows promise in treating gynecologic cancers.

Where can I find the materials from Vincerx's presentation?

Presentation materials will be available on Vincerx's website following the event.

What is Vincerx Pharma's focus?

Vincerx Pharma focuses on developing innovative therapeutics for unmet medical needs in cancer treatment.